Management and outcome of major bleeding in patients on triple therapy after coronary stenting. Clues from the WARfarin and coronary STENTing (WAR-STENT) registry

In patients on triple therapy of warfarin, aspirin and clopidogrel after coronary stenting (PCI-S), the incidence of major bleeding is relevant. No data are available on the management, and associated outcome, of major bleeding in this patient subset, wherein the decision to discontinue one rather than another antithrombotic agent may be difficult because of the concomitant risks of thromboembolism, stent thrombosis and recurrent coronary events.